Organigram Global Inc

Análisis de la acción Organigram Global Inc (OGI)

$1.180

-0.029 (-2.48%)Al cierre

Loading chart…
High
1.210
Open
1.200
VWAP
1.19
Vol
140.01K
Mkt Cap
164.80M
Low
1.170
Amount
166.15K
EV/EBITDA, TTM
3.77

Organigram Global Inc. is focused on producing cannabis for adult recreational consumers, as well as developing international business partnerships. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT, Collective Project, Fetch and DEBUNK. It operates facilities in Moncton, New Brunswick and LacSuperieur, Quebec, with an edibles manufacturing facility in Winnipeg, Manitoba. It operates two additional cannabis processing facilities in Southwestern Ontario: one in Aylmer and the other in London. The facility in Aylmer houses CO2 and Hydrocarbon extraction capabilities, and is optimized for formulation refinement, post-processing of minor cannabinoids, and pre-roll production. The facility in London is optimized for labeling, packaging, and national fulfillment. Its subsidiaries include Organigram Inc. and Motif Labs Ltd.

AI analysis of Organigram Global Inc (OGI)

buy

Given the current price of 1.215 and a recent record Q3 revenue of 105.8 million CAD, OrganiGram Holdings Inc appears to be a good buy right now. The company has shown a remarkable turnaround in revenue growth, with a 49% year-over-year increase, and a strong adjusted EBITDA of 13.4 million CAD, reflecting operational improvements. However, the main risk is the recent net loss of 0.9 million CAD in Q2 2026, which raises concerns about profitability stability.

Métricas de valoración

The current forward P/E ratio for Organigram Global Inc (OGI) is 17.04, compared to its 5-year average forward P/E of -0.95.

Forward P/E

Fair
5Y Average P/E
-0.95
Current P/E
17.04
Sobrevalorada
48.39
Infravalorada
-50.29

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-22.90
Current EV/EBITDA
3.77
Sobrevalorada
222.32
Infravalorada
-268.13

Forward P/S

Fair
5Y Average P/S
1.80
Current P/S
0.37
Sobrevalorada
3.26
Infravalorada
0.35

Alphio AI Price Scenarios for OGI

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%OGI

$1.86

Precio del escenario

B

Base

Base · 50%OGI

$1.64

Precio del escenario

B

Bear

Bear · 25%OGI

$1.37

Precio del escenario

Cronología de eventos

2026-08-11 (ET)

06:30:00

Organigram Reports Q3 Adjusted EBITDA of $13.4M

2026-05-12 (ET)

06:10:00

Company Reports Q2 Adjusted EBITDA of $870K

06:10:00

Sees FY26 Adjusted EBITDA Higher than FY25, CapEx Below $10M

2026-04-15 (ET)

12:10:00

Organigram Completes Acquisition of Sanity Group for €107.3M

2026-03-23 (ET)

06:10:00

Organigram Recommends Shareholders Vote FOR Sanity Group Acquisition

Noticias

OGI FAQ — answered by Alphio AI

Organigram Global Inc. is focused on producing cannabis for adult recreational consumers, as well as developing international business partnerships. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT, Collective Project, Fetch and DEBUNK. It operates facilities in Moncton, New Brunswick and LacSuperieur, Quebec, with an edibles manufacturing facility in Winnipeg, Manitoba. It operates two additional cannabis processing facilities in Southwestern Ontario: one in Aylmer and the other in London. The facility in Aylmer houses CO2 and Hydrocarbon extraction capabilities, and is optimized for formulation refinement, post-processing of minor cannabinoids, and pre-roll production. The facility in London is optimized for labeling, packaging, and national fulfillment. Its subsidiaries include Organigram Inc. and Motif Labs Ltd. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Given the current price of 1.215 and a recent record Q3 revenue of 105.8 million CAD, OrganiGram Holdings Inc appears to be a good buy right now. The company has shown a remarkable turnaround in revenue growth, with a 49% year-over-year increase, and a strong adjusted EBITDA of 13.4 million CAD, reflecting operational improvements. However, the main risk is the recent net loss of 0.9 million CAD in Q2 2026, which raises concerns about profitability stability.

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empieza gratis